The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting mounting operational challenges within the biotechnology sector, Evotec SE has announced a sharp downward revision of its long-term financial targets. According to analyst reports, the company lowered its 2026 annual revenue guidance to a range of €570 million to €610 million, while projecting negative adjusted Group EBITDA between -€70 million and -€105 million for the full year. This announcement triggered a collapse in the share price, which dropped 11.93% to hit a new 52-week low of $2.14.
This decline comes amid heavy selling pressure after the company attributed the revision to delayed revenue from strategic partnerships and slower conversion of commercial activities. Compared to sector peers, Evotec is facing pressures similar to those seen by firms like Sartorius, which previously warned of weak demand; consequently, Macquarie and Cowen & Co slashed their price targets following the news according to research citations. Notably, Germany's trade balance showed a surplus of €19.1 billion in May per market data, highlighting a divergence between general industrial performance and specialized sectors like biotech.
Investors are now monitoring the company's ability to regain market confidence, with EVO shares standing at $2.43 (at close July 13, 2026) per market data. Looking at the economic calendar, there are no direct catalysts scheduled for the company in the coming seven days; however, attention remains on any operational updates regarding the timelines for new agreements, which the company noted are taking longer than expected to materialize.